BioCentury
ARTICLE | Finance

Meat of the matter

Infectious disease play Novira raises A round to move into clinic in HBV

September 3, 2012 7:00 AM UTC

Novira Therapeutics Inc.'s $23 million series A round will allow the company to move its discovery-stage viral capsid assembly inhibitor through Phase II trials in HBV, according to Canaan Partners' Tim Shannon.

Canaan co-led the round with 5AM Ventures. Both firms are new investors in Novira...